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Summary
Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone 
fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone 
versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes.
Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with 
type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes 
clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by 
site and previous cardiovascular events, to add-on pioglitazone (15–45 mg) or a sulfonylurea (5–15 mg glibenclamide, 
2–6 mg glimepiride, or 30–120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event 
adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards 
model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or 
urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned 
participants with baseline data available and without any protocol violations in relation to inclusion or exclusion 
criteria). This study is registered with ClinicalTrials.gov, number NCT00700856.
Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 
1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], 
gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped 
early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 
105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-years) who were 
given sulfonylureas (hazard ratio 0·96, 95% CI 0·74–1·26, p=0·79). Fewer patients had hypoglycaemias in the 
pioglitazone group than in the sulfonylureas group (148 [10%] vs 508 [34%], p<0·0001). Moderate weight gain (less 
than 2 kg, on average) occurred in both groups. Rates of heart failure, bladder cancer, and fractures were not 
significantly different between treatment groups.
Interpretation In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas 
(mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available 
and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was 
associated with fewer hypoglycaemia events.
Funding Italian Medicines Agency, Diabete Ricerca, and Italian Diabetes Society.
Introduction
Cardiovascular disease is the most common cause of 
morbidity and mortality in patients with diabetes.1 
Findings from the UK Prospective Diabetes Study 
(UKPDS) have shown that good glycaemic control 
established at the time of diagnosis can reduce the 
incidence of cardiovascular events and microvascular 
complications in patients with type 2 diabetes.2,3 
However, maintaining appropriate glucose control over 
time is difficult. In UKPDS, only 50% of patients had 
attained satisfactory glucose control with monotherapy 
(metformin, sulfonylurea, or insulin) 3 years after 
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diagnosis, the proportion decreasing to 25% after 
9 years.4
The progressive nature of type 2 diabetes requires a 
stepwise therapeutic approach combining different 
antihyperglycaemic drugs. Currently, metformin is the 
recommended first-line drug, but there is considerable 
uncertainty about the best therapeutic option in 
patients whose glycaemia is inadequately controlled 
with met formin alone.5,6 Sulfonylureas are very effective 
glucose-lowering drugs, which are still largely used in 
combination with metformin,7 despite their well-
documented side-effects, particularly hypoglycaemia 
and weight gain. Because the cardiovascular safety of 
sulfonylureas has been questioned,8,9 assessment of the 
cardiovascular effects of this drug class (as well as its 
long-term effect on glucose control and general safety) 
compared with other treatment strategies is needed.
Thiazolidinediones (glitazones) are glucose-lowering 
drugs that are associated with a minimal risk of 
hypoglycaemia and can ameliorate insulin resistance and 
cardiovascular risk factors; therefore, they have great 
potential for cardiovascular protection. Although 
rosiglitazone has been dismissed because of a purported 
increase in cardiovascular risk, pioglitazone has been 
shown to reduce ischaemic cardiovascular events in 
placebo-controlled studies of individuals with and 
without diabetes,10,11 although concerns remain about its 
potential side-effects.12–15
We undertook a pragmatic trial to compare, in usual 
clinical practice conditions, the long-term effects of a 
sulfonylurea or pioglitazone as add-on therapy to 
metformin in the treatment of patients with type 2 diabetes 
inadequately controlled with metformin monotherapy. 
The aim of the study was to compare the long-term effect 
of these two therapeutic options with respect to incidence 
of cardiovascular events, as well as their effects on glucose 
control and safety.
Methods
Study design and participants
The Thiazolidinediones Or Sulfonylureas Cardio vascular 
Accidents Intervention Trial (TOSCA.IT) was a 
pragmatic, multicentre, randomised, parallel-group, 
clinical trial done at 57 diabetes clinics in Italy. We used a 
multicentre prospective, randomised, open label, blinded 
endpoint (PROBE) study design. The ethics committees 
of the coordinating centre (Federico II University of 
Naples, Italy) and of each trial site approved the study 
protocol and all participants provided written informed 
consent before entering the study.
Details of the study design have been reported 
previously.16 Briefly, eligible participants were men and 
women (aged 50–75 years) who had type 2 diabetes of at 
least 2 years’ duration and were on stable treatment with 
full-dose metformin (2–3 g per day), had an HbA1c of 
7·0–9·0% (53–75 mmol/mol), and a BMI of 20–45 kg/m². 
Key exclusion criteria were acute cardiovascular events in 
the previous 6 months, chronic heart failure (New York 
Heart Association class 1 or higher), and a serum 
creatinine concentration greater than 132 µmol/L (a 
Research in context
Evidence before this study
We searched PubMed, ScienceDirect, and the Cochrane Library 
for articles published in English between Jan 1, 1997, and 
Dec 31, 2007, with search terms “type 2 diabetes”, “metformin”, 
“pioglitazone”, “sulfonylureas”, and “cardiovascular events”, or 
“cardiovascular disease” or “cardiovascular mortality”, or 
“glycated haemoglobin”, or “treatment failure” or “heart 
failure”. In patients with type 2 diabetes, metformin is the 
recommended first-line drug treatment, but there is 
considerable uncertainty as to the best add-on treatment in 
patients whose glycaemia is inadequately controlled with 
metformin alone. Sulfonylureas are the most widely used 
choice, but their cardiovascular safety is uncertain. Pioglitazone 
could represent a suitable alternative, in view of the evidence 
supporting its protective effect on ischaemic cardiovascular 
disease, although concerns remain about possible clinically 
relevant side-effects. The cardiovascular effects, glycaemic 
effects, and safety of these therapeutic approaches have not 
previously been compared in a long-term, head-to-head trial.
Added value of this study
The TOSCA.IT trial provides a direct comparison of two widely 
available and affordable second-line treatment regimens for 
patients with type 2 diabetes. The patients enrolled represent 
an almost primary prevention population that is usually 
neglected in trials done to investigate the cardiovascular 
effects of glucose-lowering drugs. The results showed that, 
if used appropriately, in terms of patient selection and dose, 
both pioglitazone and a sulfonylurea (glimepiride or gliclazide) 
as add-on to metformin are associated with similarly low rates 
of cardiovascular events and few clinically relevant side-effects. 
Our findings also suggest that pioglitazone could be 
advantageous compared with sulfonylureas in terms of 
durability of glycaemic control and frequency of 
hypoglycaemia.
Implications of all the available evidence
Our results lend support to current treatment guidelines for 
type 2 diabetes, particularly in relation to patients with a low 
cardiovascular risk, by suggesting that both pioglitazone and 
sulfonylureas (glimepiride or gliclazide) are suitable alternatives 
as add-on treatment when metformin alone fails to provide 
adequate glycaemic control.
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contraindication for the use of metformin at full dose). A 
full list of inclusion and exclusion criteria is provided in 
the appendix.
Randomisation and masking
Participants were randomly assigned (1:1) to either 
pioglitazone or a sulfonylurea as add-on to metformin. 
In accordance with local practice, glibenclamide, 
gliclazide, or glimepiride could be prescribed in the 
sulfonylurea group. Permuted blocks randomisation 
(block size 10) was done centrally via an interactive 
telephone system and was stratified by site and history 
of cardiovascular events. Participants and investigators 
were aware of treatment assignment. The components 
of the primary outcome and some selected adverse 
events of particular interest with respect to the study 
drugs (heart failure, pathological fractures, macular 
oedema, and neoplasms) were adjudicated by an 
independent endpoint committee unaware of treatment-
group assignment. The prespecified criteria for event 
adjudication are listed in the appendix.
An independent data and safety monitoring board 
provided surveillance of the study and had access to the 
unblinded data.
Procedures
Follow-up visits were scheduled at 1, 3, and 6 months 
after randomisation and every 6 months thereafter until 
study end. More frequent visits could be scheduled if 
deemed appropriate, based on clinical conditions or 
glucose-control status. Drug compliance, efficacy, and 
safety were assessed at each visit; doses of the drugs 
taken, temporary or permanent discontinuation of the 
study drugs, and the reasons for discontinuation were 
reported in the study records on the basis of a patient’s 
interview. Metformin dose remained unchanged 
throughout the study whereas the study add-on drugs 
could be titrated at the investigators’ discretion, on the 
basis of home glucose monitoring and occurrence of 
hypoglycaemia. Doses of 15–45 mg for pioglitazone, 
5–15 mg for glibenclamide, 30–120 mg for gliclazide, and 
2–6 mg for glimepiride were used, as deemed appropriate 
by the treating physician. All drugs were given orally. 
Home glucose monitoring was done in accordance with 
local practice. For the specific purposes of the study, 
patients were required to provide glucose measurements 
at fasting and 2 h after lunch and dinner on one day per week 
in the 4 weeks preceding each follow-up visit.
We measured HbA1c every 6 months; for values 
of 8% (64 mmol/mol) or higher, an extra visit was 
scheduled 3 months apart. We defined treatment failure 
of the assigned treatment as an HbA1c of 8% (64 mmol/mol) 
or higher on two consecutive visits 3 months apart. If 
treatment failure occurred, basal insulin glargine and, 
subsequently, prandial short-acting insulin analogues 
were added, in a stepwise manner, to the previous 
treatment, which continued at the same doses. We 
assessed fasting plasma lipids, C-reactive protein, 
microalbuminuria, and electrocardiograms (ECG) 
annually. Investigators were encouraged to treat 
cardiovascular risk factors in accordance with current 
American Diabetes Association and Italian guidelines.6,17
Due to safety concerns regarding the risk of bladder 
cancer with pioglitazone,18 the study protocol was amended 
in 2012 to include assessment of haematuria at each study 
visit. Biochemical analyses and ECG reading were done 
centrally. We collected information on symptoms and 
events possibly related to the study outcomes at each visit 
with specific questionnaires. Patients who prematurely 
discontinued the study drugs were followed up for 
ascertainment of cardiovascular outcomes and in-
formation on vital status was obtained from the national 
health registry using the patient’s fiscal code as identifier 
for patients lost to follow-up.
Outcomes
The primary outcome was a composite of first occurrence 
of all-cause death, non-fatal myocardial infarction 
(including silent myocardial infarction), non-fatal stroke, 
or urgent coronary revascularisation. Because the study 
was designed as a pragmatic trial, the selection of all-
cause death as part of the primary composite outcome 
was clearly of relevance because this is the most robustly 
ascertained endpoint, and arguably of the greatest clinical 
significance.
The key secondary outcome was a composite of 
ischaemic cardiovascular disease, which included first 
occurrence of sudden death, fatal and non-fatal 
myocardial infarction (including silent myocardial 
infarction), fatal and non-fatal stroke, leg amputation 
above the ankle, and any revascularisation of the 
coronary, leg, or carotid arteries.
An expanded composite cardiovascular outcome was 
among the remaining secondary outcomes—this 
included the primary outcome plus heart failure; any 
revascularisation of the coronary, leg, or carotid arteries; 
angina confirmed by new ECG abnormalities; and 
intermittent claudication with an ankle-brachial index 
less than 0·90. At the suggestion of the data and safety 
monitoring board, heart failure, initially listed only 
among the components of the expanded secondary 
cardiovascular outcome, was also made a stand-alone 
secondary outcome to be adjudicated by the endpoint 
committee (approved protocol amendment, July, 2010). 
The other secondary outcomes were new or worsening 
nephropathy (ie, new-onset macroalbuminuria, twice the 
baseline levels of serum creatinine, creatinine clearance 
reduction of ≥20 mL/min per 1·73m², plasma creatinine 
>290 µmol/L, or need for permanent dialysis), time to 
failure of hypoglycaemic treatment (defined as 
HbA1c ≥8% [≥64 mmol/mol] on two consecutive visits 
3 months apart), and changes in HbA1c and major 
cardiovascular risk factors (BMI, waist circumference, 
plasma lipids, blood pressure, microalbuminuria, 
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C-reactive protein, estimated glomerular filtration rate 
[eGFR], and heart rate) over time.
Adverse events were reported in the electronic case 
report form using ad-hoc forms, in which the 
investigators also explained whether in their judgement 
the event was causally related to the study drugs. For all 
reported cases of cancer, heart failure, bone fractures, 
and macular oedema, the investigators were required to 
provide documentation and these events were reviewed 
and adjudicated by the event committee. Adverse events 
of special interest were hypoglycaemic episodes defined 
as a documented glucose value of less than 3·3 mmol/L 
and graded as moderate (not requiring help for 
treatment) or severe (requiring assistance for treatment).
The study was designed to be event driven. The initial 
sample size calculation was based on an estimated 
primary endpoint rate of 3·5% per year, with the study 
intended to have 80% power to detect a reduction of 20% 
in the primary outcome in either group versus the other, 
based on the results of the PROACTIVE trial.10 On the 
basis of these assumptions, 652 events were needed for 
the primary efficacy analysis. Therefore, 4396 patients 
had to be enrolled and followed up for at least 4 years; 
assuming a trial discontinuation rate of 15%, 5172 patients 
needed to be recruited and randomly assigned (2586 in 
each treatment group).
However, because of the lower than expected rate of 
recruitment and because the number of participants 
discontinuing the study was lower than initially foreseen, 
an approved protocol amendment (January, 2012) 
subsequently reduced the sample size requirement. 
Accordingly, 3371 patients should have been enrolled to 
expect the 498 endpoint events needed to detect a 
20% reduction in the incidence of events with a statistical 
power of 80% (hazard ratio [HR] 0·80, p=0·05 [one-sided 
log-rank test]), assuming an estimated occurrence rate of 
the primary endpoint of 3·5% per year and a 5% loss to 
follow-up. Nonetheless, nearly 9 years after the beginning 
of the study, the number of events needed was still not 
reached, and a futility analysis was done as recommended 
by the data and safety monitoring board.
3028 patients were recruited between Sept 18, 2008, and 
Jan 15, 2014, given the difficulties in further prolonging 
the enrolment phase (organisational problems related to 
investigators’ retirements and reorganisation of the 
national health-care system whereby small hospitals or 
medical centres were consolidated). The observed event 
rate during follow-up was lower than expected, with 
213 adjudicated primary endpoint events in total. 
Following the data and safety monitoring board’s 
recommendation, a futility analysis for the primary 
endpoint using a frequentist approach19 was done in 
March 31, 2017. The results of this analysis showed that, if 
the future data distribution followed the current trend 
(the most plausible hypothesis), the probability of 
observing a significant positive result (ie, an HR of 0·80, 
two-sided log-rank test) at the planned end of follow-up 
would be as low as 5%. On the basis of the futility analysis, 
the study was discontinued on May 23, 2017.
The trial efficacy analysis was done in the modified 
intention-to-treat population, which included all 
randomly assigned participants with baseline data 
available and without any protocol violations in relation 
to inclusion or exclusion criteria. Data from the patients 
who completed or discontinued the trial without having 
an outcome were censored from the day of their last visit; 
events occurring after that visit were not included. We 
also did a post-hoc on-treatment analysis for the primary 
and secondary composite cardiovascular outcomes and 
components of the primary outcome, which included 
only data from follow-up trial periods during which 
patients were taking the assigned study drug; patients 
were censored at the time of permanent study drug 
Figure 1: Trial profile
GPT=glutamic pyruvic transaminase. *Same number included in the safety analysis population and the post-hoc 
on-treatment analysis population.
1535 assigned to pioglitazone
148 did not complete trial
 86 withdrew consent 
 34 lost to follow-up
 2 poor compliance
 4 personal reason
 14 patient's decision
 1 clinician's decision
 4 reasons not given
 3 adverse events
  1 macula lutea oedema
  1 liver transplantation
  1 adverse drug reaction
  1103 completed the trial or died
           432 discontinued study 
                    drug prematurely 
1535 included in the modified 
 intention-to-treat 
 population*
6 protocol violation or no 
    baseline data
1493 assigned to sulfonylureas
112 did not complete trial
 58 withdrew consent 
 27 lost to follow-up
 3 poor compliance
 6 personal reason
 11 patient's decision
 0 clinician's decision
 3 reasons not given
 4 adverse events
  2 Alzheimer’s disease
  1 increase in serum 
   creatinine levels
  1 increase in GPT 
   concentration
   1255 completed the trial or died
             238 discontinued study 
                      drug prematurely
1493 included in the modified 
 intention-to-treat 
 population*
7 protocol violation or no 
    baseline data
4956 screened
1915 excluded
           1571 HbA1c inclusion criteria not confirmed by central 
      laboratory
             289 patient’s decision
                33 intercurrent illness
                 11 elevated serum creatinine
                 11 intolerance to metformin
3041 randomly assigned
See Online for appendix
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discontinuation (with data included in the analysis for an 
additional 30 days after study drug discontinuation). The 
safety analysis set includes only participants exposed to 
the trial medications. Participants were regarded as 
exposed to the trial medications as long as they had taken 
at least one dose of pioglitazone or sulfonylurea.
We assessed incidence rates using cumulative incidence 
curves that were compared (metformin plus pioglitazone 
vs metformin plus sulfonylurea) using log-rank analysis. 
The analysis of the time-dependent primary endpoint 
and secondary endpoints was based on a two-sided Cox 
proportional-hazards model. We compared incidence and 
severity of hypoglycaemic events between groups using a 
Poisson regression model with correction for 
overdispersion. We did prespecified subgroup analyses 
for the primary outcome by sex (between treatments in 
men and women), age (<60 years or ≥60 years), BMI 
(≤30 kg/m² or >30 kg/m²), duration of diabetes (≤8 years 
or >8 years), HbA1c (≤8·0% [64mmol/mol] or >8·0% 
[64 mmol/mol]), and eGFR (<60 mL/min per 1·73 m² or 
≥60 mL/min per 1·73 m²).
We compared proportions in the two treatment groups 
using the continuity adjusted χ² test, or two-sided Fisher’s 
exact test, as appropriate. We estimated the mean 
differences between the trial groups for HbA1c, BMI, 
bodyweight, waist circumference, lipid profile, blood 
pressure, eGFR, heart rate, C-reactive protein, and 
urinary albumin-to-creatinine ratio using a mixed model 
for repeated measurements.20
All statistical analyses were done with SAS (version 9.4). 
Data are expressed as mean (SD), mean (SE), or n (%), as 
appropriate. All reported p values are two-sided and are 
not adjusted for multiple comparisons.
This study is registered with ClinicalTrials.gov, number 
NCT00700856.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Sept 18, 2008, and Jan 15, 2014, 4956 patients 
were screened and 3041 were randomly assigned to a 
treatment group although 13 of these patients were 
excluded because of protocol violation or because they 
had no baseline data. Therefore, 3028 patients were 
included in the intention-to-treat analysis (figure 1), with 
1535 patients in the metformin plus pioglitazone group 
and 1493 in the metformin plus sulfonylureas group. In 
the metformin plus sulfonylureas group, 24 (2%) patients 
were given glibenclamide, 723 (48%) were given 
glimepiride, and 745 (50%) were given gliclazide. On the 
basis of a futility analysis, the study was stopped when the 
median follow-up was 57·3 months (IQR 42·2–60·2); 
follow-up time was similar in the two treatment groups 
(appendix). Overall, 1387 (90%) patients in the 
pioglitazone group and 1381 (92%) in the sulfonylureas 
group attended a final visit or had died by the end of the 
study (figure 1, appendix). The study groups were well 
balanced with respect to baseline demographic 
characteristics, diabetes duration, HbA1c, and major 
cardiovascular risk factors (table 1). At randomisation, 
patients were started at the lowest recommended dose of 
the study drugs. The mean dose of pioglitazone used was 
23·0 mg (SD 8·6), and for the sulfonylureas the mean 
doses were 7·6 mg (4·0) for glibenclamide, 42·0 mg (18·6) 
for gliclazide, and 2·5 mg (0·9) for glimepiride. 
Premature permanent discontinuation of the study 
medications was significantly more frequent in the 
metformin plus pioglitazone group than in the metformin 
plus sulfonylureas group (432 [28%] vs 238 [16%], 
p<0·0001; appendix).
The primary cardiovascular composite outcome occurred 
in 105 patients (7%, 1·5 per 100 person-years) who were 
Metformin 
plus pioglitazone 
(n=1535)
Metformin 
plus sulfonylurea 
(n=1493)
Overall 
(n=3028)
Age (years) 62·4 (6·4) 62·2 (6·5) 62·3 (6·5)
Sex
Men 909 (59%) 865 (58%) 1774 (59%)
Women 626 (41%) 628 (42%) 1254 (41%)
BMI (kg/m²) 30·2 (4·4) 30·4 (4·5) 30·3 (4·5)
Cardiovascular risk factors
Smokers 281 (18%) 252 (17%) 533 (18%)
LDL cholesterol (mmol/L) 2·67 (0·81) 2·66 (0·82) 2·67 (0·81)
HDL cholesterol (mmol/L) 1·20 (0·34) 1·20 (0·33) 1·20 (0·34)
Triglycerides (mmol/L) 1·72 (1·04) 1·73 (0·93) 1·73 (1·00)
Systolic blood pressure (mm Hg) 134·3 (15·1) 133·7 (14·2) 134·0 (14·7)
Diastolic blood pressure (mm Hg) 79·6 (8·7) 79·6 (8·1) 79·6 (8·4)
Microalbuminuria 321 (21%) 312 (21%) 633 (21%)
Diabetes characteristics
Duration of diabetes (years) 8·4 (5·6) 8·5 (5·8) 8·5 (5·7)
HbA1c (%) 7·67 (0·50) 7·69 (0·51) 7·68 (0·50)
HbA1c (mmol/mol) 60·3 (5·4) 60·5 (5·6) 60·4 (5·5)
Previous cardiovascular history
Previous cardiovascular disease* 187 (12%) 148 (10%) 335 (11%)
Previous acute myocardial 
infarction
109 (7%) 86 (6%) 195 (6%)
Previous stroke 28 (2%) 13 (1%) 41 (1%)
Previous acute coronary syndrome 39 (3%) 40 (3%) 79 (3%)
Carotid artery revascularisation 14 (1%) 12 (1%) 26 (1%)
Coronary artery revascularisation 105 (7%) 101 (7%) 206 (7%)
Use of cardiovascular drugs
Antihypertensive drugs 1072 (70%) 1049 (70%) 2121 (70%)
Lipid-lowering drugs 888 (58%) 847 (57%) 1735 (57%)
Antiplatelet drugs 644 (42%) 574 (38%) 1218 (40%)
Data are mean (SD) or n (%). *Some patients had more than one condition.
Table 1: Baseline characteristics
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given pioglitazone and 108 patients (7%, 1·5 per 100 person-
years) who were given sulfonylureas. There were no 
significant between-group differences in the composite 
primary outcome (HR 0·96, 95% CI 0·74–1·26, p=0·79) or 
in its components (figure 2, table 2). The key secondary 
outcome occurred in 74 patients (5%, 1·1 per 100 person-
years) in the pioglitazone group and in 83 patients 
(6%, 1·2 per 100 person-years) in the sulfonylureas group 
(HR 0·88, 0·65–1·21, p=0·44). Details on the individual 
components of the key secondary outcome are provided in 
the appendix. The proportion of patients who had the 
expanded cardiovascular outcome was also similar in the 
two study groups (HR 1·03, 0·82–1·28, p=0·81; table 2). 
Analysis of the primary endpoint by prespecified baseline 
categories of sex, age, BMI, diabetes duration, HbA1c, 
and eGFR did not show significant between-group 
differences or significant interactions (appendix). A post-
hoc comparison of the incidence of the primary outcome 
between the two study groups after exclusion of patients 
with a previous cardiovascular event also did not show 
any significant difference between the treatment groups 
(HR 0·99, 0·73–1·34, p=0·94; appendix). Heart failure 
occurred in 19 (1%) patients in the pioglitazone group and 
12 (1%) patients in the sulfonylureas group (HR 1·57, 
0·76–3·24, p=0·22).
We also did a post-hoc on-treatment analysis of the 
primary and secondary composite cardiovascular 
outcomes and of the components of the primary 
outcome. Only events occurring in patients while they 
were taking study drugs, or after 30 days from 
discontinuation, were included in this analysis. In this 
data subset, the incidence of the primary outcome was 
Metformin plus pioglitazone 
(n=1535)
Metformin plus sulfonylurea 
(n=1493)
Hazard ratio (95% CI) p value
n (%) n per 100 
patient-years
n (%) n per 100 
patient-years
Intention-to-treat analysis
Primary composite outcome* 105 (7%) 1·5 108 (7%) 1·5 0·96 (0·74–1·26) 0·79
All-cause death 55 (4%) 0·8 50 (3%) 0·7 1·10 (0·75–1·61) 0·63
Non-fatal myocardial infarction 
(including silent myocardial infarction)
21 (1%) 0·3 24 (2%) 0·3 0·87 (0·48–1·55) 0·63
Non-fatal stroke 16 (1%) 0·2 20 (1%) 0·3 0·79 (0·41–1·53) 0·49
Urgent coronary revascularisation 31 (2%) 0·4 34 (2%) 0·5 0·91 (0·56–1·48) 0·70
Key secondary outcome† 74 (5%) 1·1 83 (6%) 1·2 0·88 (0·65–1·21) 0·44
Expanded composite outcome‡ 163 (11%) 2·3 157 (11%) 2·3 1·03 (0·82–1·28) 0·81
On-treatment analysis (post hoc)
Primary composite outcome* 73 (5%) 1·2 99 (7%) 1·5 0·82 (0·60–1·10) 0·19
All-cause death 43 (3%) 0·7 45 (3%) 0·7 1·08 (0·71–1·65) 0·70
Non-fatal myocardial infarction 
(including silent myocardial infarction)
13 (1%) 0·2 23 (2%) 0·4 0·63 (0·32–1·24) 0·18
Non-fatal stroke 11 (1%) 0·2 18 (1%) 0·3 0·67 (0·32–1·42) 0·30
Urgent coronary revascularisation 18 (1%) 0·3 32 (2%) 0·5 0·62 (0·35–1·11) 0·11
Key secondary outcome† 48 (3%) 0·8 79 (5%) 1·2 0·67 (0·47–0·96) 0·03
Expanded composite outcome‡ 122 (8%) 2·1 147 (10%) 2·3 0·90 (0·71–1·15) 0·41
*The primary composite outcome was the first occurrence of all-cause death, non-fatal myocardial infarction (including silent myocardial infarction), non-fatal stroke, or urgent 
coronary revascularisation. †The key secondary outcome includes the first occurrence of sudden death, fatal and non-fatal myocardial infarction (including silent myocardial 
infarction), fatal and non-fatal stroke, major leg amputation (above the ankle), and any revascularisation of the coronary, carotid, or leg arteries. ‡The expanded composite 
outcome includes first occurrence of all-cause death, non-fatal myocardial infarction (including silent myocardial infarction), non-fatal stroke, heart failure, any revascularisation 
of the coronary, carotid, or leg arteries, angina confirmed by electrocardiogram changes, and intermittent claudication with an ankle brachial index of less than 0·90.
Table 2: Primary and secondary cardiovascular outcomes
Figure 2: Cumulative incidence of the composite primary outcome
The primary composite outcome was the first occurrence of all-cause death, non-fatal myocardial infarction 
(including silent myocardial infarction), non-fatal stroke, or urgent coronary revascularisation. HR=hazard ratio.
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1·2 per 100 person-years in the pioglitazone group and 
1·5 per 100 person-years in the sulfonylureas group 
(HR 0·82, 95% CI 0·60–1·10, p=0·19; table 2); none of 
the components of the primary outcome was significantly 
different between the study groups. However, the key 
secondary outcome, a composite of ischaemic cardio-
vascular events, was significantly reduced in the 
pioglitazone group compared with the sulfonylureas 
group in the post-hoc on-treatment analysis (HR 0·67, 
95% CI 0·47–0·96, p=0·03; table 2). The expanded 
composite cardiovascular outcome did not differ between 
the groups in this post-hoc analysis (table 2).
New or worsening nephropathy occurred in 282 (23%) 
patients in the pioglitazone group and 270 (23%) patients 
in the sulfonylureas group, in the intention-to-treat 
analysis (HR 1·03, 95% CI 0·89–1·19, p=0·37). In both 
groups, HbA1c decreased significantly after starting 
treatment with the study drugs and remained significantly 
lower than at baseline throughout the study (figure 3, 
appendix) with 39% of study participants who had good 
glucose control (HbA1c ≤7%, 53 mmol/mol) over a median 
observation period of almost 5 years with both treatment 
regimens. Mean HbA1c over time was slightly lower for 
patients in the pioglitazone group than for patients in the 
sulfonylureas group (7·24% [SD 0·20] vs 7·30% [SD 0·21], 
p=0·01; 55 mm/mol vs 56 mmol/mol). Fewer patients had 
treatment failure with pioglitazone than with sulfonylureas 
(193 patients [13%] vs 295 [20%]; HR 0·63, 95% CI 
0·52–0·75, p<0·0001; figure 4). Accordingly, fewer 
patients in the pioglitazone group were prescribed rescue 
insulin therapy during the study (164 [11%] vs 233 [16%], 
p<0·0001).
Figure 3: Cardiovascular risk factors over time
Data are mean values for HbA1c (A), BMI (B), waist circumference (C), HDL cholesterol (D), LDL cholesterol (E), and triglycerides (F) during the trial period. Error bars 
show SEs. Data were estimated on the basis of measurements taken at scheduled visits. The analyses are based on a mixed model for repeated measurements, taking 
into account within-participant correlation. p values were calculated with a mixed model for repeated measurements.
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In both groups, BMI changed slightly during the first 
2 years after starting treatment with the study drugs 
(corresponding to a weight gain of less than 2 kg, on 
average, in both groups), and then levelled off until the end 
of the study (figure 3). No significant between-group 
differences were recorded during the study for BMI, waist 
circumference, LDL cholesterol, and triglycerides, whereas 
HDL-cholesterol concentrations were significantly higher 
in the pioglitazone group (figure 3, appendix). As for other 
cardiovascular risk factors, blood pressure, albumin-to-
creatinine ratio, eGFR, and C-reactive protein were similar 
in the two treatment groups during the study period.
The overall incidence of serious adverse events was 
similar in the pioglitazone and sulfonylureas groups 
(table 3, appendix). The occurrence of confirmed 
malignant neoplasms, including bladder cancer, was also 
similar. Pathological bone fractures and macular oedema 
occurred in a small proportion of patients, with no 
significant differences between treatment groups. 
Further details on all adverse events are reported in the 
appendix. Severe hypoglycaemic events were fairly 
uncommon, but were more frequent with sulfonylureas 
(table 4).
Discussion
In this long-term pragmatic trial, the incidence of 
cardiovascular events was similar with sulfonylureas 
(mostly glimepiride and gliclazide) or pioglitazone as 
add-on to metformin in patients with type 2 diabetes 
inadequately controlled with metformin alone. Both 
treatments were effective overall and were not associated 
with high risk of clinically relevant side-effects; however, 
patients given pioglitazone had better durability of 
glycaemia control, less frequent hypoglycaemia, and 
higher HDL-cholesterol concentrations than patients 
given sulfonylureas.
We detected no difference between the treatment 
groups in the incidence of any of the prespecified 
cardiovascular outcomes, including fatal and non-fatal 
myocardial infarction or stroke, or all-cause death, during 
the study. Findings of previous cardiovascular outcome 
trials with pioglitazone in people with (PROACTIVE10) or 
without (IRIS11) diabetes support its beneficial effects on 
ischaemic cardiovascular outcomes, although total 
cardiovascular events and all-cause deaths were not 
significantly reduced in these studies. The reasons for 
the discrepancy between TOSCA.IT and previous 
findings might relate not only to the outcomes assessed, 
but also to features of the study population and the 
choice of comparator. In both PROACTIVE and IRIS, 
patients had previous cardiovascular events, whereas in 
our study population the prevalence of baseline 
cardiovascular diseases was low (11%) and the annual 
rate of events was among the lowest reported in the 
scientific literature for patients with type 2 diabetes of 
similar age.21 In this low-risk population, the beneficial 
effects of pioglitazone on cardiovascular diseases might 
be too small to be detected in absolute terms; however, 
results of the post-hoc on-treatment analysis of the key 
secondary endpoint, a composite outcome of ischaemic 
cardiovascular events, are in agreement with findings 
from previous studies.10,11
Metformin 
plus pioglitazone 
(n=1535)
Metformin 
plus sulfonylurea 
(n=1493)
p value
Serious adverse events* 208 (14%) 195 (13%) 0·73
Malignant neoplasms† 78 (5%) 71 (5%) 0·74
Lung 9 (1%) 3 (<1%) 0·15
Colorectal 12 (1%) 9 (1%) 0·66
Breast 3 (<1%) 4 (<1%) 0·72
Bladder 8 (1%) 8 (1%) 1·00
Pancreatic 2 (<1%) 6 (<1%) 0·17
Other 44 (3%) 41 (3%) 0·91
Pathological fractures† 6 (<1%) 4 (<1%) 0·75
Men 3/909 (<1%) 1/865 (<1%) 0·62
Women 3/626 (<1%) 3/628 (<1%) 1·00
Macular oedema† 7 (<1%) 3 (<1%) 0·34
Respiratory, thoracic, 
and mediastinal disorders
16 (1%) 5 (<1%) 0·03
Data are n (%), unless otherwise specified. Proportion of participants experiencing adverse events was compared using 
the continuity-adjusted χ² test, or two-sided Fisher’s exact test, as appropriate. Data are for patients who had one or 
more events among those who received at least one dose of assigned study drug. Adverse events were selected on the 
basis of the most relevant side-effects of the study drugs. All adverse events occurring at significantly different rates 
between the two study groups are also reported. Data are based on investigator-reported adverse events, unless 
otherwise specified. A complete list of serious adverse events according to system organ class is provided in the 
appendix. Adverse event categories were defined in accordance with the system organ class in the Medical Dictionary 
of Regulatory Activities. *A serious adverse event was defined as death, a life-threatening episode, hospital admission 
or prolongation of existing hospital admission, or a persistent or substantial disability. †Neoplasms, pathological 
fractures, and macular oedema were adjudicated.
Table 3: Selected adverse events
Figure 4: Cumulative incidence of treatment failure
Failure of hypoglycaemic treatment was defined as HbA1c of 8% (64 mmol/mol) or above on two consecutive visits 
3 months apart. HR=hazard ratio.
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The use of an active comparator, rather than placebo, 
might have further affected the study outcomes. The 
hypothesis that the comparator drugs might have had a 
beneficial effect on cardiovascular events cannot be 
dismissed, because the cardiovascular effects of 
sulfonylureas are far from clearly established. In the 
UKPDS, the combination of sulfonylureas and metformin 
was associated with higher diabetes-related mortality than 
sulfonylureas alone;22 conversely, in other intervention 
trials, treatment with sulfonylureas was associated with 
similar or lower risk of cardiovascular events compared 
with other therapeutic strategies.23,24 The potentially 
increased cardiovascular risk associated with sulfonylureas 
has been largely attributed to glibenclamide.25 In our 
study, only 2% of patients were given glibenclamide, with 
the remaining participants receiving glimepiride or 
gliclazide.
The results of TOSCA.IT, which was done in the 
context of usual clinical practice, show that both 
treatment regimens are effective in maintaining 
satisfactory blood glucose control for a median 
observation period of almost 5 years in most patients, 
with a relatively low rate of clinically relevant side-effects 
associated with the study drugs. Specifically, bodyweight 
increased slightly during the study period in both 
treatment groups, with no significant difference between 
groups. A more substantial increase in bodyweight was 
reported in previous studies with pioglitazone;10,11 the 
discrepancy might be partly explained by the exclusion of 
patients with heart failure or reduced renal function 
from our study, since such patients are predisposed to 
fluid retention, a relevant cause of weight gain with use 
of pioglitazone. Compared with sulfo nylureas, 
pioglitazone as add-on to metformin achieved marginally 
lower HbA1c values, a lower risk of hypo glycaemias 
(partly because of the higher proportion of patients on 
insulin in the sulfonylureas group due to a higher rate of 
treatment failure), and improved HDL-cholesterol 
concentrations, in agreement with previous data.26,27 
Patients in the pioglitazone group achieved a significantly 
better durability of glycaemic control, as reported in a 
previous study with rosiglitazone.28
As to the long-term safety of the study drugs, heart 
failure, although numerically more frequent with 
pioglitazone, occurred in fairly few patients overall and 
did not differ significantly between the treatment groups. 
This finding could be partly ascribed to the selection 
criteria of the study, which excluded patients with heart 
failure in New York Heart class 1 or higher, and is in 
agreement with the results of the IRIS trial,11 in which 
the (non-diabetes) study population was at low risk for 
heart failure. This result might also be related to the dose 
of pioglitazone used in TOSCA.IT, which on average was 
about half the maximum recommended dose. The 
occurrence of bladder cancer was also low and not 
significantly different between the two study groups, and 
the same was true for pathological fractures and macular 
oedema. Nevertheless, the present study had too few of 
these events to allow any definitive conclusions to be 
drawn. Altogether, the results of TOSCA.IT suggest that, 
if used appropriately (in terms of patient selection and 
dose), pioglitazone is generally not associated with a high 
risk of clinically relevant side-effects. However, as many 
as 28% of the participants assigned to pioglitazone 
discontinued the study drug prematurely; in many cases, 
this discontinuation was due to the safety concerns 
raised in 2012, when the drug was withdrawn from the 
market in France and Germany. A similarly high rate of 
drug discontinuation with pioglitazone was also reported 
in the IRIS study.11
Major strengths of this study are the head-to-head 
comparison, within an usual care setting, of 
two therapeutic strategies suitable as second-line 
treatment for type 2 diabetes, as well as the long follow-
up period. Further more, the study drugs are among the 
least expensive glucose-lowering drugs available. All 
recent cardiovascular outcome trials with newer 
antidiabetes drugs are placebo-controlled and do not 
provide comparative efficacy and a risk–benefit balance 
of different drug combinations.29 The only ongoing 
cardiovascular outcome trial with an active comparator 
is CAROLINA,30 in which the dipeptidyl peptidase-4 
inhibitor linagliptin is being compared with the 
sulfonylurea glimepiride. Moreover, most of the 
cardiovascular outcome trials reported so far have had a 
much shorter duration than did TOSCA.IT. The vascular 
effects of antidiabetes drugs took about 5 years to be 
detected in both the UKPDS and the Diabetes Control 
and Complications Trial, and possible effects on cancer 
and fractures will probably take a similar time to become 
apparent.2,3 Therefore, trials such as TOSCA.IT, which 
have a sufficiently long follow-up, are needed to 
effectively address the crucial question of the 
comparative balance of risks and benefits in relation to 
relevant treatment strategies for type 2 diabetes. A 
further strength of our study is that the patients enrolled 
were mostly free of previous cardiovascular events. To 
date, information about the effect of different types of 
glucose-lowering drugs in this group of low-risk patients 
is scarce. Unfortunately, because patients with a previous 
Metformin 
plus pioglitazone 
(n=1535)
Metformin plus 
sulfonylurea 
(n=1493)
Incidence rate ratio 
(95% CI)
p value
Patients Events Patients Events
Severe 
hypoglycaemic events
1 (<1%) 2 24 (2%) 33 0·06 (0·01–0·25) <0·0001
Moderate 
hypoglycaemic events
147 (10%) 515 484 (32%) 1868 0·27 (0·24–0·30) <0·0001
Data are n (%) or n, unless otherwise specified. Hypoglycaemic events were defined as a glucose value lower than 
3·3 mmol/L and graded as moderate (not requiring help for treatment) or severe (requiring assistance for treatment). 
Data are shown for patients who received at least one dose of assigned study drugs.
Table 4: Hypoglycaemic events
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cardiovascular event in our study population were so 
few, it was not possible to do a meaningful subanalysis 
in this group.
This study also has limitations. First, the incidence of 
the primary endpoint was lower than anticipated, leading 
to a lower statistical power than planned. The low 
incidence of cardiovascular events might be related to the 
characteristics of the patients enrolled and to the 
intensive treatment of cardiovascular risk factors. A 
further limitation is the rate of discontinuation of the 
study drugs, which, although in line with the IRIS trial,11 
was unbalanced between the study groups 
(ie, significantly higher in patients treated with 
pioglitazone). This difference in discontinuation might 
dilute differences between the study groups, as suggested 
by the results of the post-hoc on-treatment analysis. 
Additionally, the study is based on a PROBE design; 
therefore, although the components of the primary 
outcome and some selected adverse events (ie, heart 
failure, fractures, macular oedema, and neoplasms) were 
adjudicated by an independent committee unaware of 
treatment group assignment, both patients and study 
physicians were not masked to treatment assignment.
In conclusion, the results from this pragmatic trial 
show that, within an usual clinical setting and over a 
median observation period of almost 5 years, both 
sulfonylureas (mostly glimepiride and gliclazide) or 
pioglitazone have a similar effect as add-on to 
metformin on the incidence of total cardiovascular 
events. This finding suggests that in patients with type 2 
diabetes without cardiovascular diseases and with 
reasonable glucose control, the choice of the treatment 
strategy when metformin monotherapy fails might not 
have a major effect on cardiovascular complications. 
Additionally, the two treatment strategies effectively 
controlled blood glucose in the long term, with few 
clinically relevant side-effects. Altogether, our study 
suggests that both pioglitazone or a sulfonylurea are 
suitable alternatives as add-on treatment to metformin, 
although the combination of metformin and pio-
glitazone was advantageous in terms of durability of 
glycaemic control and frequency of hypoglycaemia. 
These results are relevant for public health in view of 
the affordability and wide availability of the study drugs. 
Further studies are needed to assess whether similar 
results could be obtained in head-to-head comparisons 
of these commonly used drugs with newer glucose-
lowering drugs.
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